



**Contact:**

Dave Kwajewski  
DKwajewski@pion-inc.com  
(508) 868-0034

**FOR IMMEDIATE RELEASE**

**Pion and BASF Collaborate on Drug Development & Delivery Publication**

*μFLUX™ and μDISS Profiler™ used to increase understanding of drug supersaturation*

**BILLERICA, MA, USA** —January 15, 2015—Pion Inc. has joined forces with Dr. Shaukat Ali from BASF to develop a new protocol for testing drug supersaturation. This process was described in the Jan/Feb issue of *Drug Development & Delivery*. The article, entitled EXCIPIENT UPDATE - Soluplus®: An Understanding of Supersaturation From Amorphous Solid Dispersions, describes the use of Pion's μFLUX™ and μDISS Profiler™ to increase understanding of the interplay between achieved supersaturation of amorphous solid dispersion of a model low soluble drug carbamazepine and its effect on flux of the drug through an artificial membrane.

“As more low soluble compounds enter the pharmaceutical development stage it is becoming more and more challenging to formulate such compounds into drug products with suitable absorption properties,” says Konstantin Tsinman, director of Science and Research at Pion Inc. “Amorphous solid dispersion with solubilizing, as well as precipitation inhibiting polymers/excipients, is one of the first choices formulation scientists employ to overcome the solubility issues.”

Pion's μFLUX™ and μDISS Profiler™ were used to measure flux of free drug in the receiver compartment separated from the donor by an artificial membrane. The μProfiler™ is a situ fiber optic dissolution monitoring system, and the μFLUX™ is an *in vitro* instrument for the prediction of *in vivo* dissolution and permeation. Using the μFLUX™ device allows researchers to simultaneously monitor the flux of free drugs in solutions from a complex solid dispersion system.

“This article demonstrates how the μFLUX™ apparatus together with the μDISS Profiler™ can help performing efficient comparative screening of different formulations based on the flux response they produce,” explains Konstantin. “Looking at the flux rather than solubility or dissolution alone takes into account the complex interplay between solubilization and free drug concentration that influences absorption and bioavailability of the drugs.”

Pion's research and development team is dedicated to developing products that continue to address the industry's growing bioavailability challenges.

The full article is available online at [Drug-dev.com](http://Drug-dev.com).

**About Pion Inc.**

*Pion Inc.* develops and manufactures instrumentation for compound testing in pharmaceutical R&D. These include high precision fiber optic-based analytical instruments for solubility and dissolution measurements, as well as complete systems for permeability (PAMPA), solubility, and ionization. Additionally, Pion provides CRO services for solubility, permeability, dissolution, pKa, lipophilicity testing. More information is available at [www.pion-inc.com](http://www.pion-inc.com).

###